PRCA can also be a result of therapy with certain recombinant forms of EPO, probably because of production of neutralizing antibodies that inhibit the erythropoietic activity of endogenous EPO and recombinant erythropoiesis-stimulating agents (ESAs) (Casadevall, 2005). This evidence concerns the gene EPO and pure red-cell aplasia.